ClinicalTrials.gg
RecruitingNCT06962371GUARDIANUpdated May 8, 2025

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

An interventional study of cerebral embolic protection in Transcatheter Aortic Valve Implantation (TAVI), Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, sponsored by Transverse Medical, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Transverse Medical, Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Aortic Valve Stenosis with a site in Australia — 10 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Australia.

Planned enrollment
23rd of 28
30 · median 358
Started
2025
with 2 others
No phase
28 of 35
8 open now
Primary completion
2026-03
later than 5 of 14 live
Registered
32nd of 35
by date
Lead sponsor
1 of 35
Transverse Medical, Inc.

Among the 35 studies in Aortic Valve Stenosis with a site in Australia, this one is the 23rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 28 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 32nd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

10 of the 35 studies in Aortic Valve Stenosis with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Aortic Valve Stenosis with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.

Read the detailed description

This is a prospective, single-arm, multi-center, open study to assess the clinical performance and safety of the Point-Guard CEPD during a TAVR procedure.

03

Conditions studied

  • Transcatheter Aortic Valve Implantation (TAVI)
  • Aortic Valve Stenosis
  • Transcatheter Aortic Valve Replacement

Keywords

  • CEP
  • Cerebral Embolic Protection
  • CEP Device
  • TAVR
  • TAVI
  • stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is ≥18 years of age;
  2. The patient meets indications for Transcatheter Aortic Valve Replacement (TAVR);
  3. The patient is willing to comply with protocol-specified follow-up evaluations;
  4. The patient has been informed of the nature of the study, agrees to its provisions, and has provided written , approved by the appropriate Institutional Review Board or Ethics Committee.

Exclusion criteria

Exclusion Criteria:

  1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).
  2. Anatomy that precludes safe delivery and retrieval of the device.
  3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period.
  4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up.
  5. Patients with uncontrolled bleeding disorders.
  6. Patients who are pregnant, as confirmed by a positive pregnancy test.

General Exclusion Criteria

  1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).
  2. Anatomy that precludes safe delivery and retrieval of the investigational device.
  3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period.
  4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up.
  5. Patients with uncontrolled bleeding disorders.
  1. Patients who are pregnant, as confirmed by a positive pregnancy test.

Magnetic resonance imaging exclusion criteria:

  1. (BMI) and/or total body weight precluding imaging in scanner.
  2. to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
  3. High risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g., subjects with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block).
  4. Existing or planned implantation of a pacemaker or defibrillator implantation within the first 3 days after TAVR.
  5. Claustrophobia precluding MRI scanning.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Point-Guard

    Device: cerebral embolic protection

Interventions

  • Devicecerebral embolic protection

    Use of Transverse Medical Inc. Point-Guard CEP device.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    Technical success, defined as successful deployment, positioning and retrieval per the Instructions For Use (IFU), with minimal device interference, and as outlined below: * Deployment of the Point-Guard filter unit from the Delivery sheath into the aortic arch; * Positioning of the Point-Guard device within the aortic arch; * Retrieving and removing the Point-Guard device intact; * Minimal device interference (operator assessed).

    Time frame: From beginning of TAVI procedure to end.

  2. Primary Safety Endpoints

    1. Primary Safety Endpoint: TAVR procedure complications associated with the delivery, positioning, and removal of the test device. 2. Primary Safety Endpoint: MACCE (all death, all stroke, and acute kidney injury class 3) within 72 hours or discharge, whatever occurs first and at 30 days.

    Time frame: Beginning of TAVI procedure to 30 days post-procedure.

Other outcomes

  1. Observational Endpoints

    1. Reduction in Median Total New Lesion Volume in whole-brain as assessed by traditional 1.5T DW-MRI as soon as possible and within twenty-four (24) hours post-procedure. \[Time Frame: Day 0-1 days Post-Procedure\] - Total new lesion volume is defined as the sum of all diffusion- positive new cerebral lesions in post-TAVR DW-MRI relative to the pre-TAVR DW-MRI scans. (in mm\^3)

    Time frame: 24 hours pre-procedure to 24 hours post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD to be used for internal device design validation only.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2026, 11 months after the start.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 11 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
May 8, 2025
StartActual
Apr 7, 2025
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06962371
Lead sponsor
Transverse Medical, Inc.
Collaborators
Medical Metrics Diagnostics, Inc, Monash Health, Transverse Medical Australia, Ascend Clinical
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Apr 7, 2025
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
May 8, 2025

Study contacts

Erin Spiegel, PhD
Contact
erin.spiegel@transversemedical.com
+13033252945
Blair Holman
Contact
blair.holman@transversemedical.com
+13033252945
Robert Gooley, MD
principal investigator · Monash Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion